DGAP-News: Medios AG / Key word(s): Preliminary Results/Forecast
Medios AG fulfils forecast for financial year 2018 and is expecting to set new records in 2019
Berlin, 14 February 2019 - Medios AG ('Medios'), one of the leading Specialty Pharma companies in Germany, is expecting another record year after significant sales and earnings growth in 2018. According to preliminary calculations (IFRS), group sales in the period from January to December 2018 increased year on year by 29.3 per cent to EUR 327.9 million (previous year EUR 253.6 million). Group earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted for extraordinary expenses*, rose by 41.6 per cent to EUR 12.1 million (previous year EUR 8.5 million). Group earnings before taxes (EBT), adjusted for extraordinary expenses*, climbed by 37.7 per cent to EUR 11.0 million (previous year EUR 8.0 million). Thereby, all the forecasts of the Management Board for the financial year 2018 were met.
Manfred Schneider, CEO of Medios AG: '2018 was another record year for Medios, thanks to the consistent implementation of our growth strategy and to the ongoing high demand for individualised therapies. We have expanded our partner network, increased our product range and extended our indication areas. In the financial year 2019, we want to continue on our dynamic growth path. Therefore, we are especially investing strongly in setting up a new business unit, 'Drug Safety', and in establishing our new 'Medios Apotheke' brand.'
Matthias Gärtner, CFO of Medios AG: 'We have achieved our ambitious targets in the financial year 2018. Our operating earnings rose faster than sales again. Thereby, we have become even more profitable. We intend to maintain this trend in 2019, while continuing our high growth rate.'
Due to the acquisitions in the financial year 2018 and the further company growth, Medios expects higher depreciation and amortisation from the current year onwards. In order to illustrate this adequately in the financial reports and to present its operating performance transparently, Medios is including EBITDA as another key performance indicator in its financial reporting with immediate effect.
Further record figures expected for 2019
* Adjusted for extraordinary expenses of around EUR 3.47 million in total for a) stock options totalling EUR 2.51 million from the financial years 2017 and 2018 (non-cash), b) start-up expenses in the financial year 2018 of EUR 0.64 million for the laboratories acquired in September 2017 and c) of EUR 0.32 million for the acquisition of the operating units from BerlinApotheke Schneider & Oleski oHG in the financial year 2018 (non-cash)
About Medios AG
Medios AG is Germany's first publicly listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard) and Hamburg-Hannover Stock Exchange.
|Phone:||+49 30 232 566 - 800|
|Fax:||+49 30 232 566 - 801|
|Listed:||Regulated Market in Frankfurt (General Standard), Hamburg; Regulated Unofficial Market in Dusseldorf|
|End of News||DGAP News Service|